Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6537085 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL11193240 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL5518553 | 1.00 | GABRR1 (0.46) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL13825268 | 0.87 | — | — | |
| SCHEMBL7110047 | 0.87 | — | — | |
| SCHEMBL12434857 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL15984957 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL13026596 | 0.86 | SLC7A5 (0.46) | GABRR1ENPEP | |
| SCHEMBL12293187 | 0.86 | GABRR1 (0.37) | GABRR1CYP1A2TP53FOLH1NAALAD2 | |
| SCHEMBL20088918 | 0.86 | ACE2 (0.38) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | GABRR1 3059/4885CYP1A2 2776/4885TP53 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.